TG Therapeutics, Inc. (TGTX)
56.05
+1.78
(+3.28%)
USD |
NASDAQ |
Aug 24, 16:00
56.45
+0.40
(+0.71%)
After-Hours: 20:00
TG Therapeutics EPS Diluted (Quarterly) : 0.0495 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0495 |
| March 31, 2026 | 0.1236 |
| December 31, 2025 | 0.1446 |
| September 30, 2025 | 2.428 |
| June 30, 2025 | 0.1734 |
| March 31, 2025 | 0.0311 |
| December 31, 2024 | 0.1456 |
| September 30, 2024 | 0.0241 |
| June 30, 2024 | 0.0432 |
| March 31, 2024 | -0.0732 |
| December 31, 2023 | -0.1008 |
| September 30, 2023 | 0.7309 |
| June 30, 2023 | -0.3365 |
| March 31, 2023 | -0.2796 |
| December 31, 2022 | -0.3865 |
| September 30, 2022 | -0.2647 |
| June 30, 2022 | -0.3006 |
| March 31, 2022 | -0.5135 |
| December 31, 2021 | -0.7041 |
| September 30, 2021 | -0.647 |
| June 30, 2021 | -0.5944 |
| March 31, 2021 | -0.6871 |
| December 31, 2020 | -0.7109 |
| September 30, 2020 | -0.7314 |
| June 30, 2020 | -0.4707 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.4847 |
| December 31, 2019 | -0.4137 |
| September 30, 2019 | -0.6907 |
| June 30, 2019 | -0.4172 |
| March 31, 2019 | -0.4331 |
| December 31, 2018 | -0.6422 |
| September 30, 2018 | -0.434 |
| June 30, 2018 | -0.5944 |
| March 31, 2018 | -0.5879 |
| December 31, 2017 | -0.46 |
| September 30, 2017 | -0.48 |
| June 30, 2017 | -0.448 |
| March 31, 2017 | -0.5216 |
| December 31, 2016 | -0.48 |
| September 30, 2016 | -0.50 |
| June 30, 2016 | -0.33 |
| March 31, 2016 | -0.28 |
| December 31, 2015 | -0.37 |
| September 30, 2015 | -0.28 |
| June 30, 2015 | -0.38 |
| March 31, 2015 | -0.35 |
| December 31, 2014 | -0.48 |
| September 30, 2014 | -0.51 |
| June 30, 2014 | -0.36 |
| March 31, 2014 | -0.25 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Krystal Biotech, Inc. | 1.786 |
| MAIA Biotechnology, Inc. | -0.1307 |
| Vericel Corp. | 0.0422 |
| Incyte Corp. | 2.812 |
| Regeneron Pharmaceuticals, Inc. | 12.23 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 7.781M |
| Revenue (Quarterly) | 240.34M |
| Total Expenses (Quarterly) | 232.55M |
| Enterprise Value | 8.510B |
| Gross Profit Margin (Quarterly) | 82.86% |
| Profit Margin (Quarterly) | 3.24% |
| Earnings Yield | 4.90% |
| Operating Earnings Yield | 1.53% |
| Normalized Earnings Yield | 4.992 |